Skip to main content
. 2023 Jul 10;14:1173728. doi: 10.3389/fimmu.2023.1173728

Figure 3.

Figure 3

Preparation of Lipo-anti-PD-L1-P4. (A) Protocol for the preparation of Lipo-anti-PD-L1-P4. (B) Representative result of liposome size distribution. Average size: 44 nm; polydispersity index: 0.22; ζ-potential: –20.1 kV; P4 concentration: 78.5 μg/mL. (C) P4 leakage test. DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DSPE-PEG-Maleimide, N-[(3-maleimide-1-oxopropyl)aminopropyl polyethyleneglycol-carbamyl] distearoylphosphatidyl-ethanolamine; EDTA, ethylenediaminetetraacetic acid; Lipo-anti-PD-L1-P4, liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated P4; P4, progesterone; PBS, phosphate-buffered saline; r.t., room temperature.